Skip to content

Bioenergetic Technology

Using Bioenergetic Technology to heal our bodies and minds

Menu

  • Home
  • About us
  • Contact us

Cornerstone Pharmaceuticals Announces Positive Phase I Data for CPI-613 in Relapsed or Refractory AML Patients to be …

Uncategorized and-leader, cornerstone, growing, phase, positive-data, the-growing, today-announced

CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced positive data from an ongoing Phase …

More:
Cornerstone Pharmaceuticals Announces Positive Phase I Data for CPI-613 in Relapsed or Refractory AML Patients to be …

Related posts:

  1. Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 in Patients With Locally …
  2. Cornerstone Pharmaceuticals to Present CPI-613 Phase I Results at 2013 American Society of Hematology Annual Meeting
  3. Cornerstone Pharmaceuticals' CPI-613 Phase I Hematologic Malignancies Trial Data Published in AACR's Clinical Cancer …
  4. Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Hodgkin's or T-Cell Non …
  • ← Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Hodgkin's or T-Cell Non …
  • Cornerstone Pharmaceuticals' CPI-613 Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting … →

Recent Posts

  • Reata gets FDA orphan drug status for bardoxolone methyl to treat PAH
  • New Subtle Energy Pattern Research Shows Increases in Cell Growth and Viability
  • Cornerstone Pharmaceuticals' CPI-613 Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting …
  • Cornerstone Pharmaceuticals Announces Positive Phase I Data for CPI-613 in Relapsed or Refractory AML Patients to be …
  • Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Hodgkin's or T-Cell Non …
Copyright © 2024 Bioenergetic Technology. All rights reserved.
Theme: Accelerate by ThemeGrill. Powered by WordPress.